Vyvanse and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is found among people who take Vyvanse, especially for people who are female, 40-49 old, have been taking the drug for 1 - 2 years.

The phase IV clinical study analyzes which people take Vyvanse and have Multiple sclerosis. It is created by eHealthMe based on reports of 22,723 people who have side effects when taking Vyvanse from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

22,723 people reported to have side effects when taking Vyvanse.
Among them, 44 people (0.19%) have Multiple sclerosis.

What is Vyvanse?

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 29,835 Vyvanse users for its effectiveness, alternative drugs and more.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 2,179 drugs and 1,315 conditions by eHealthMe.

Number of Vyvanse and Multiple sclerosis reports submitted per year:

Time on Vyvanse when people have Multiple sclerosis *:

Gender of people who have Multiple sclerosis when taking Vyvanse *:

female: 79.07 %
male: 20.93 %

Age of people who have Multiple sclerosis when taking Vyvanse *:

Common drugs people take besides Vyvanse *:

Common side effects people have besides Multiple sclerosis *:

Fall: 8 people, 18.18%
Weakness: 8 people, 18.18%
Nausea (feeling of having an urge to vomit): 8 people, 18.18%
Fatigue (feeling of tiredness): 8 people, 18.18%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 7 people, 15.91%
Headache (pain in head): 7 people, 15.91%
Visual Impairment: 6 people, 13.64%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 13.64%
Disturbance In Attention: 5 people, 11.36%
Pain: 5 people, 11.36%

Common conditions people have *:

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 7 people, 15.91%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 5 people, 11.36%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 9.09%
Stress And Anxiety: 4 people, 9.09%
Drowsiness: 4 people, 9.09%
Gait Disturbance: 3 people, 6.82%
Neuralgia (pain in one or more nerves): 3 people, 6.82%
Weakness: 3 people, 6.82%
Insomnia (sleeplessness): 3 people, 6.82%
High Blood Pressure: 2 people, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Vyvanse and have Multiple sclerosis?

Check whether Multiple sclerosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A, "Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder", Journal of central nervous system disease, 2017 Aug .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD, "Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD", Drug design, development and therapy, 2017 Jan .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P, "Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials", Drug design, development and therapy, 2013 Jan .

Related studies

How severe was Multiple sclerosis and when was it recovered:

Multiple sclerosis in Vyvanse

Expand to all the drugs that have ingredients of lisdexamfetamine dimesylate:

Multiple sclerosis and drugs with ingredients of lisdexamfetamine dimesylate (48 reports)

Alternative drugs to, pros and cons of Vyvanse:

Vyvanse (29,835 reports)

Common Vyvanse side effects:

Drug ineffective: 2,848 reports
Stress and anxiety: 1,466 reports
Fatigue (feeling of tiredness): 1,383 reports
Headache (pain in head): 1,150 reports
Insomnia (sleeplessness): 1,089 reports
Depression: 977 reports

Browse all side effects of Vyvanse:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Multiple sclerosis treatments and more:

Multiple sclerosis (734,949 reports)

COVID vaccines that are related to Multiple sclerosis:

Common drugs associated with Multiple sclerosis:

All the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (2,179 drugs)

Common conditions associated with Multiple sclerosis:

Relapsing-remitting multiple sclerosis: 2,659 reports
Pain: 971 reports
Depression: 831 reports
Rheumatoid arthritis: 748 reports

All the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,315 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lisdexamfetamine dimesylate (the active ingredients of Vyvanse) and Vyvanse (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.